Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
information fournie par Boursorama CP 09/11/2020 à 18:00
Ajouter Boursorama à vos sources

Strasbourg, France and Lund, Sweden - November 9, 2020 - 6:00 p.m. CET- Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today present new data on BT-001, a novel oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment, in the SITC abstract "BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment" (Abstract number: 594).

.../...

Valeurs associées

TRANSGENE
0,8470 EUR Euronext Paris -0,82%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
HAFFNER ENERGY
0,717 +12,56%
Pétrole Brent
102,7 +4,21%
CAC 40
8 123,41 -0,39%
2CRSI
30,88 +5,18%
SOITEC
150,65 -0,92%
Chargement...

Pages les plus populaires

L'offre BoursoBank